Research status and recent advances of lupus podocytopathy
-
摘要: 狼疮足细胞病（lupus podocytopathy，LP）以广泛足突消失为特征，无外周毛细血管壁增生和免疫复合物沉积，是狼疮肾炎（lupus nephritis，LN）的一种特殊类型。目前LP发病机制并未阐明，糖皮质激素联合非特异性免疫抑制剂的应用可缓解病情，但用药后复发率高是LP治疗的棘手问题。本综述就LP的组织病理、发病机制及治疗的现状进行报道。Abstract: As a special type of lupus nephritis,lupus podocytopathy(LP) is characterized by diffuse epithelial cell foot process effacement and absence of peripheral capillary wall proliferation and immune complex deposition.Currently the pathogenesis of LP has remained elusive.Using glucocorticoids and immunosuppressive agents can alleviate the severity of disease.However,high recurrence rate of LP has become a thorny problem.This review summarized the histopathology,pathogenesis and treatment of LP.
-
Keywords:
- Lupus nephritis /
- Podocytes /
- Histopathology /
- Autophagy /
- Rituximab
-
-
[1] Hertig A,Droz D,Lesavre P,et al.SLE and idiopathic nephrotic syndrome:coincidence or not?[J].Am J Kidney Dis,2002,40(6):1179-1184.DOI: 10.1053/ajkd.2002.36875.
[2] Shea-Simonds P,Cairns TD,Roufosse C,et al.Lupus podocytopathy[J].Rheumatology(Oxford),2009,48(12):1616-1618.DOI: 10.1093/rheumatology/kep256.
[3] Oliva-Damaso N,Juan PY,Oliva-Damaso E,et al.Lupus podocytopathy:an overview[J].Adv Chronic Kidney Dis,2019,26(5):369-375.DOI: 10.1053/j.ackd.2019.08.011.
[4] 中国狼疮肾炎诊断和治疗指南编写组.中国狼疮肾炎诊断和治疗指南[J].中华医学杂志,2019,99(44):3441-3455.DOI: 10.3760/cma.j.issn.0376-2491.2019.44.001. Chinese Lupus Nephritis Diagnosis and Treatment Guidelines Compilation Group.Chinese Lupus Nephritis Diagnosis and Treatment Guidelines[J].Natl Med J China,2019,99(44):3441-3455.DOI: 10.3760/cma.j.issn.0376-2491.2019.44.001.
[5] Muray Cases S,Herranz Marín MT,Alcázar Fajardo C,et al.Podocytopathy as debut of a systemic lupus erythematosus[J].Nefrologia(Engl Ed),2018,38(6):674-675.DOI: 10.1016/j.nefro.2018.03.006.
[6] Hu W,Chen Y,Wang S,et al.Clinical-morphological features and outcomes of lupus podocytopathy[J].Clin J Am Soc Nephrol,2016,11(4):585-592.DOI: 10.2215/cjn.06720615.
[7] Bomback AS.Nonproliferative forms of lupus nephritis:an overview[J].Rheum Dis Clin North Am,2018,44(4):561-569.DOI: 10.1016/j.rdc.2018.06.003.
[8] Shalhoub RJ.Pathogenesis of lipoid nephrosis:a disorder of T-cell function[J].Lancet,1974,2(7880):556-560.DOI: 10.1016/s0140-6736(74)91880-7.
[9] van Den Berg JG,Aten J,Annink C,et al.Interleukin-4 and-13 promote basolateral secretion of H(+)and cathepsin L by glomerular epithelial cells[J].Am J Physiol Renal Physiol,2002,282(1):F26-F33.DOI: 10.1152/ajprenal.0102.2001.
[10] Liu LL,Qin Y,Cai JF,et al.Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome[J].Clin Immunol,2011,139(3):314-320.DOI: 10.1016/j.clim.2011.02.018.
[11] Saleem MA,Kobayashi Y.Cell biology and genetics of minimal change disease[J].F1000Res,2016,5:F1000 Faculty Rev-F1000412.DOI: 10.12688/f1000research.7300.1.
[12] You GQ,Cao HX,Yan L,et al.MicroRNA-10a-3p mediates Th17/Treg cell balance and improves renal injury by inhibiting REG3A in lupus nephritis[J].Int Immunopharmacol,2020,88:106891.DOI: 10.1016/j.intimp.2020.106891.
[13] Mishra OP,Kumar R,Narayan G,et al.Toll-like receptor 3(TLR-3),TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome[J].Pediatr Nephrol,2017,32(8):1355-1361.DOI: 10.1007/s00467-017-3613-8.
[14] Cara-Fuentes G,Venkatareddy M,Verma R,et al.Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse[J].Pediatr Nephrol,2020,35(10):1887-1896.DOI: 10.1007/s00467-020-04541-3.
[15] Garin EH,Diaz LN,Mu W,et al.Urinary CD80 excretion increases in idiopathic minimal-change disease[J].J Am Soc Nephrol,2009,20(2):260-266.DOI: 10.1681/ASN.2007080836.
[16] Ichinose K,Ushigusa T,Nishino A,et al.Lupus nephritis IgG induction of calcium/calmodulin-dependent protein kinase IV expression in podocytes and alteration of their function[J].Arthritis Rheumatol,2016,68(4):944-952.DOI: 10.1002/art.39499.
[17] Lee JM,Yang JW,Kronbichler A,et al.Increased serum soluble urokinase-type plasminogen activator receptor(suPAR)levels in FSGS:a meta-analysis[J].J Immunol Res,2019,2019:5679518.DOI: 10.1155/2019/5679518.
[18] Qin DD,Song D,Huang J,et al.Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis:a large cohort study from China[J].Lupus,2015,24(6):546-557.DOI: 10.1177/0961203314558857.
[19] Zhou XJ,Klionsky DJ,Zhang H.Podocytes and autophagy:a potential therapeutic target in lupus nephritis[J].Autophagy,2019,15(5):908-912.DOI: 10.1080/15548627.2019.1580512.
[20] Hillmann A,Wardemann H,Pap T,et al.Uptake of SLE autoantibodies by podocytes[J].Ann Rheum Dis,2012,71(Suppl 1):A32.3-A33.DOI: 10.1136/annrheumdis-2011-201234.2.
[21] Dong YD,Zhang ZM,Liu HZ,et al.Exacerbating lupus nephritis following BPA exposure is associated with abnormal autophagy in MRL/lpr mice[J].Am J Transl Res,2020,12(2):649-659.
[22] Jin J,Zhao L,Zou WL,et al.Activation of cyclooxygenase-2 by ATF4 during endoplasmic reticulum stress regulates kidney podocyte autophagy induced by lupus nephritis[J].Cell Physiol Biochem,2018,48(2):753-764.DOI: 10.1159/000491904.
[23] DOI: 10.1136/bcr-2018-227860.
[24] Hu W,Niu G,Li H,et al.The association between expression of IFIT1 in podocytes of MRL/lpr mice and the renal pathological changes it causes:an animal study[J].Oncotarget,2016,7(47):76464-76470.DOI: 10.18632/oncotarget.13045.
[25] Markowitz GS,Nasr SH,Stokes MB,et al.Treatment with IFN is associated with collapsing focal segmental glomerulosclerosis[J].Clin J Am Soc Nephrol,2010,5(4):607-615.DOI: 10.2215/CJN.07311009.
[26] Bomback AS.A pregnant woman with lupus and nephrotic-range proteinuria[J].Clin J Am Soc Nephrol,2017,12(9):1534-1537.DOI: 10.2215/CJN.13251216.
[27] Tsuji K,Takatsu Y,Katayama Y,et al.Podocytopathy as ‘stand-alone’ involvement in systemic lupus erythematosus:a case report[J].Lupus,2020,29(9):1148-1150.DOI: 10.1177/0961203320935988.
[28] 他克莫司在狼疮肾炎中应用的中国专家共识讨论组.他克莫司在狼疮肾炎中应用的中国专家共识[J].中华风湿病学杂志,2017,21(7):483-485.DOI: 10.3760/cma.j.issn.1007-7480.2017.07.012. Chinese Expert Consensus Discussion Group on the Application of Tacrolimus in Lupus Nephritis.Chinese Expert Consensus on the Application of Tacrolimus in Lupus Nephritis[J].Chin J Rheumatol,2017,21(7):483-485.DOI: 10.3760/cma.j.issn.1007-7480.2017.07.012.
[29] Jesus D,Rodrigues M,da Silva JAP,et al.Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis[J].Lupus,2018,27(8):1358-1362.DOI: 10.1177/0961203318758508.
[30] Yu F,Haas M,Glassock R,et al.Redefining lupus nephritis:clinical implications of pathophysiologic subtypes[J].Nat Rev Nephrol,2017,13(8):483-495.DOI: 10.1038/nrneph.2017.85.
[31] Wang Y,Yu F,Song D,et al.Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system:a large cohort study from a single centre[J].Rheumatology(Oxford),2014,53(7):1235-1244.DOI: 10.1093/rheumatology/ket491.
[32] Xiong XL,Li H,Jin M,et al.A case of lupus podocyte disease complicated with acute renal failure[J].Chin J Rheumatol,2015,19(4):270-271,封3.DOI: 10.3760/cma.j.issn.1007-7480.2015.04.013. [33] Liu K,Mohan C.Altered B-cell signaling in lupus[J].Autoimmun Rev,2009,8(3):214-218.DOI: 10.1016/j.autrev.2008.07.048.
[34] Kotagiri P,Martin A,Hughes P,et al.Single-dose rituximab in refractory lupus nephritis[J].Intern Med J,2016,46(8):899-901.DOI: 10.1111/imj.13136.
[35] Ravani P,Rossi R,Bonanni A,et al.Rituximab in children with steroid-dependent nephrotic syndrome:a multicenter,open-label,noninferiority,randomized controlled trial[J].J Am Soc Nephrol,2015,26(9):2259-2266.DOI: 10.1681/ASN.2014080799.
[36] Rovin BH,Caster DJ,Cattran DC,et al.Management and treatment of glomerular diseases(part 2):conclusions from a Kidney Disease:Improving Global Outcomes(KDIGO)Controversies Conference[J].Kidney Int,2019,95(2):281-295.DOI: 10.1016/j.kint.2018.11.008.
[37] Ruggenenti P,Ruggiero B,Cravedi P,et al.Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome[J].J Am Soc Nephrol,2014,25(4):850-863.DOI: 10.1681/ASN.2013030251.
[38] Paramalingam S,Wong DD,Dogra GK,et al.Recurrent podocytopathy in a patient with systemic lupus erythematosus[J].SAGE Open Med Case Rep,2017,5:2050313X17695997.DOI: 10.1177/2050313X17695997.
[39] 李慧娟,陈樱花,胡伟新.利妥昔单抗用于难治性狼疮性肾炎的治疗[J].肾脏病与透析肾移植杂志,2018,27(1):94-99.DOI: 10.3969/j.issn.1006-298X.2018.01.021. Li HJ,Chen YH,Hu WX.Rituximab therapy for a frequently relapsed lupus podocytopathy patient[J].Chin J Nephrol Dial Transplant,2018,27(1):94-99.DOI: 10.3969/j.issn.1006-298X.2018.01.021.
[40] Reiser J,Alachkar N.Proteinuria:abate or applaud abatacept in proteinuric kidney disease?[J].Nat Rev Nephrol,2014,10(3):128-130.DOI: 10.1038/nrneph.2013.276.
[41] Zhang CZ,Chan CCY,Cheung KF,et al.Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis[J].Clin Sci(Lond),2019,133(15):1721-1744.DOI: 10.1042/CS20190536.
[42] Ahn W,Bomback AS.Approach to diagnosis and management of primary glomerular diseases due to podocytopathies in adults:core curriculum 2020[J].Am J Kidney Dis,2020,75(6):955-964.DOI: 10.1053/j.ajkd.2019.12.019.
-
期刊类型引用(2)
1. 常海英，李东升，谢晓东. 泰它西普治疗狼疮足细胞病1例. 中华风湿病学杂志. 2022(05): 340-342 . 
百度学术
2. 刘浩歌，秦建国，韦婉，李智鹏，张正菊，焦扬. 从《金匮要略》黄汗病理论探讨系统性红斑狼疮及其经方辨治. 环球中医药. 2022(08): 1407-1410 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 396
- HTML全文浏览量: 15
- PDF下载量: 239
- 被引次数: 3
下载:
.png)